Tofacitinib Citrate Sustained-release Tablets. 枸橼酸托法替布缓释片.

Efficacy:
Tofacitinib is primarily used to treat rheumatoid arthritis requiring long-term management. Patients must meet two criteria: first, they must be currently taking methotrexate (a common cornerstone drug for rheumatoid arthritis treatment) but have not responded adequately; second, their disease has progressed to moderate to severe activity, characterized by persistent inflammation in multiple joints. This medication may also be considered for patients who cannot tolerate the side effects of methotrexate (such as nausea and abnormal liver function).
Dosage and Administration:
Tofacitinib should be swallowed whole and should only be used after a physician’s evaluation. Dosage is flexible and can be taken before or after meals, but it is important to ensure consistent daily intervals. The standard adult dose is 5 mg once daily, taken in the morning and evening, with an optimal interval of approximately 12 hours between doses. Dosage adjustments may be required for patients taking certain concomitant medications, including those taking strong CYP3A4 inhibitors (such as the antifungal drug ketoconazole) and those taking a combination of a moderate-strength CYP3A4 inhibitor and a strong CYP2C19 inhibitor (such as fluconazole). In both cases, the dosage should be adjusted to just 5 mg once daily. Adjustments for patients with abnormal liver and kidney function: Moderate or severe renal impairment (determined by creatinine clearance) and moderate liver impairment (determined by liver function tests). Both of these patients also require a single 5 mg daily dose. Special precautions are required when using these medications together: It is often used with traditional antirheumatic drugs (non-biologic DMARDs) such as methotrexate. Patients undergoing hemodialysis should take the medication immediately after completing dialysis treatment. If taken before dialysis, there is no need to take a missed dose after dialysis. Measures for abnormal blood count parameters: If the granulocyte count (a marker of immune cells in the blood count) is between 500 and 1000 cells/mm³, suspend the medication until it returns to above 1000 cells/mm³, then resume treatment at 5 mg twice daily. If the hemoglobin (a measure of anemia) drops below 8 g/dL or decreases by more than 2 g/dL in a short period of time, discontinue the medication immediately and monitor closely. Follow your doctor’s instructions once the value returns to normal. Contraindications:
Contraindicated if allergic to this product
Related Dosage Forms:
Tablets
View More